A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis

Main Article Content

Matthew Zirwas
Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA

Zoe Draelos
Dermatology Consulting Services, PLLC High Point, NC

Janet Dubois
DermResearch, Inc., Austin, TX

Leon Kircik
Mount Sinai

Angela Moore
Arlington Research Center, Arlington, TX, USA

Linda Stein Gold
Henry Ford Health System, Detroit, MI, USA

Javier Alonso-Llamazares
Driven Research LLC, Coral Gables, FL, USA

Michael Bukhalo
Arlington Dermatology, Rolling Meadows, IL, USA

Suzanne Bruce
SBA Dermatology, Houston, TX, USA

Kimmie Eads
The Indiana Clinical Trials Center, PC, Plainfield, IN, USA

Lawrence Green
George Washington University School of Medicine

Scott Guenthner
The Dermatology Center of Indiana, PC, Plainfield, IN, and The Indiana Clinical Trials Center, PC, Plainfield, IN, USA

Laura Ferris
University of Pittsburgh, Department of Dermatology, Pittsburgh, PA, USA

Seth Forman
ForCare Clinical Research, Tampa, FL, USA;

Steven Kempers
Minnesota Clinical Study Center, Fridley, MN, USA

Edward Lain
Sanova Dermatology, Austin, TX, USA;

Charles Lynde
niversity of Toronto, Toronto, Lynde Centre for Dermatology, Markham

David Pariser
Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA

David Pariser
Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA

Darryl Toth
XLR8 Medical Research and Probity Medical Research, Windsor, ON, Canada

paul Yamauchi
David Geffen UCLA School of Medicine, Los Angeles, CA, USA

Patrick Burnett
Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

David Berk
Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

Keywords

roflumilast, seborrheic dermatitis, phase 2a study

Abstract

N/A

References

1. Araya M, et al. Indian J Dermatol 2015;60:519.

2. Pärna E, et al. Acta Derm Venereol 2015; 95:312-316.

3. Clark GW, et al. Am Fam Physician 2015;91:185-190.

4. Kastarinen H, et al. Cochrane Database Syst Rev 2014:CD009446.

5. Peyrí J, et al. Actas Dermosifiliogr 2007;98:476-482. 6. Lebwohl MG, et al. N Engl J Med 2020;383:229-239

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.94

Article Details

How to Cite
Zirwas, M., Draelos, Z., Dubois, J., Kircik, L. ., Moore, A., Stein Gold, L., Alonso-Llamazares, J. ., Bukhalo, M., Bruce, S., Eads, K., Green, L., Guenthner, S., Ferris, L., Forman, S., Kempers, S., Lain, E. ., Lynde, C., Pariser, D., Pariser, D., Toth, D., Yamauchi, paul, Burnett, P., & Berk, D. (2021). A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. SKIN The Journal of Cutaneous Medicine, 5(6), s94. https://doi.org/10.25251/skin.5.supp.94
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Miscellaneous
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 7 8 9 10 11 12 13 14 15 16 > >>